Regeneron Reports Q4 2025 Results: EYLEA HD Growth, Dupixent Expansion, and Pipeline Updates

SEC 8-K Filing Notice

Company: Regeneron Pharmaceuticals, Inc. (REGN) Filing Date: 2026-01-30 Accession Number: 0000872589-26-000004

Items Filed

Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Summary

Regeneron Pharmaceuticals announced its fourth quarter and full year 2025 financial results, showcasing revenue growth driven by Dupixent and EYLEA HD. Q4 revenues increased 3% to $3.9 billion, while full-year revenues rose 1% to $14.3 billion. Dupixent global net sales, recorded by Sanofi, saw a significant increase of 34% in Q4 and 26% for the full year. EYLEA HD U.S. sales also experienced substantial growth, although total EYLEA sales declined due to the transition to the higher-dose formulation. The company highlighted several regulatory milestones, including FDA approvals for EYLEA HD in retinal vein occlusion (RVO) and Libtayo for high-risk adjuvant cutaneous squamous cell carcinoma (CSCC).

Key Takeaways

Q4 2025 revenues up 3% to $3.9 billion; FY 2025 revenues up 1% to $14.3 billion.
Dupixent global net sales increased 34% in Q4 and 26% for the full year.
EYLEA HD approved by FDA for RVO and monthly dosing flexibility; new manufacturer approved for vial filling.
Libtayo approved by FDA and EC as first immunotherapy for high-risk adjuvant CSCC.
FDA decision expected in H1 2026 for DB-OTO gene therapy for genetic hearing loss.

Analysis

Regeneron's Q4 and full-year results demonstrate the continued strength of its key products, particularly Dupixent and EYLEA HD. The successful label expansions and new filler approvals for EYLEA HD are crucial for maintaining its market position against increasing competition in the ophthalmology space. The Libtayo approval in adjuvant CSCC provides a significant new market opportunity. For investors, the focus will be on the pipeline progress, especially the upcoming FDA decisions for DB-OTO and garetosmab, as well as the Phase 3 data for fianlimab in melanoma. Competitors in the immunology, ophthalmology, and oncology spaces will be closely watching Regeneron's clinical trial results and regulatory submissions, as these will shape the competitive landscape in the coming years. The company's planned investments in manufacturing capacity signal a commitment to future growth and could potentially alleviate supply chain concerns.

This post was automatically generated from an SEC 8-K filing.